Abstract Body

Background: Highly-exposed Sero-Negative (HESN) individuals engage frequently in unprotected sexual activities, yet remain sero-negative. In order to avoid sero-conversion, these individuals likely restrict HIV infection soon after transmission. Transmission of HIV infection is established by an extremely small fraction of circulating virus. These Transmitted Founder viruses (TFV) likely arise from a single HIV clone. Recently, Parrish and Fenton-May have shown that TFV are type I interferon (IFN)-resistant compared to chronic viruses from the same individual. We hypothesize that HESN inhibit TFV more efficiently than normal donors after IFN-beta treatment.

Methods: We examined the ability of PBMC from 23 normal donors and 32 HESN donors to inhibit 10 TFV or an R5-tropic NL4-3 derivative, JM1186 after IFN-beta treatment in 14 day in vitro assays. p24 concentration was determined by alpha-LISA. HESN PBMC genotypes for selected genes were performed by custom Nimblegen Array and 454 Sequencing.

Results: After low dose IFN treatment, a significant proportion of HESN, but not normal, PBMC inhibited JM1186 infection >25% (p = 0.0017). In a separate assay, 12 HESN PBMC and 8 normal PBMC were infected with TF CH040, TF SUMA, TF CH058, 6 month chronic virus (6mo) CH058, and JM1186 and treated or not with 75 IU/ml IFN-beta. In untreated samples, only infection with TF CHO58 resulted in a significantly lower p24 in HESN (p = 0.0473). Interestingly, this virus does not trigger an IFN response in normal monocyte-derived dendritic cells. In normal PBMC, the TFV CHO40 and SUMA were more resistant to IFN-beta than JM1186 (p = 0.0031 and 0.0446, respectively). For HESN samples, the median level of IFN-beta inhibition for all viruses was lower than normal, significantly so for CH040 and SUMA, (p = 0.0027 and 0.0181, respectively). All samples were ranked for their ability to inhibit all viruses. 6 of 9 HESN donors with ranks above the distribution of normal donors had variations in genes that were reported to interact with HIV Protease, Vpr, Vpu, Integrase, and Env.

Conclusions: PBMC from HESN respond to IFN in a manner that more efficiently inhibits some viruses, including two TFV. HESN appear able to also inhibit an IFN sensitive TFV without IFN treatment. Determining the mechanism of resistance, whether it is increased responsiveness to IFN,expression of variant genes which impede viral replication, or resistance to viral countermeasures, will uncover modes of HIV resistance relevant to in vivo transmission events.